Literature DB >> 20038921

Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS.

Michael Maes1, Frank Nm Twisk.   

Abstract

There is evidence that disorders in inflammatory and oxidative and nitrosative (IO&NS) pathways and a lowered antioxidant status are important pathophysiological mechanisms underpinning myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). Important precipitating and perpetuating factors for ME/CFS are (amongst others) bacterial and viral infections; bacterial translocation due to an increased gut permeability; and psychological stress. Recently, Jason et al (2006) reported that the mean age of patients with myalgic encephalomyelitis/chronic fatigue syndrome dying from heart failure, i.e. 58.7 years, is significantly lower than the age of those dying from heart failure in the general US population, i.e. 83.1 years. These findings implicate that ME/CFS is a risk factor to cardio-vascular disorder. This review demonstrates that disorders in various IO&NS pathways provide explanations for the earlier mortality due to cardiovascular disorders in ME/CFS. These pathways are: a) chronic low grade inflammation with extended production of nuclear factor kappa B and COX-2 and increased levels of tumour necrosis factor alpha; b) increased O&NS with increased peroxide levels, and phospholipid oxidation including oxidative damage to phosphatidylinositol; c) decreased levels of specific antioxidants, i.e. coenzyme Q10, zinc and dehydroepiandrosterone-sulphate; d) bacterial translocation as a result of leaky gut; e) decreased omega-3 polyunsatutared fatty acids (PUFAs), and increased omega-6 PUFA and saturated fatty acid levels; and f) the presence of viral and bacterial infections and psychological stressors. The mechanisms whereby each of these factors may contribute towards cardio-vascular disorder in ME/CFS are discussed. ME/CFS is a multisystemic metabolic-inflammatory disorder. The aberrations in IO&NS pathways may increase the risk for cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038921

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  12 in total

Review 1.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

Review 2.  The Role of Kynurenine Pathway and NAD+ Metabolism in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Mona Dehhaghi; Hamed Kazemi Shariat Panahi; Bahar Kavyani; Benjamin Heng; Vanessa Tan; Nady Braidy; Gilles J Guillemin
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

Review 3.  Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways.

Authors:  Michael Maes; Frank N M Twisk
Journal:  BMC Med       Date:  2010-06-15       Impact factor: 8.775

Review 4.  The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-09-26       Impact factor: 5.590

Review 5.  The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances.

Authors:  Chiara De Luca; Desanka Raskovic; Valeria Pacifico; Jeffrey Chung Sheun Thai; Liudmila Korkina
Journal:  Int J Environ Res Public Health       Date:  2011-07-01       Impact factor: 3.390

Review 6.  Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Bindu D Paul; Marian D Lemle; Anthony L Komaroff; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

Review 7.  Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.

Authors:  Stanley Du Preez; Helene Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  Int J Environ Res Public Health       Date:  2021-10-12       Impact factor: 3.390

Review 8.  Oxidative Dysregulation in Early Life Stress and Posttraumatic Stress Disorder: A Comprehensive Review.

Authors:  Evangelos Karanikas; Nikolaos P Daskalakis; Agorastos Agorastos
Journal:  Brain Sci       Date:  2021-05-29

9.  Angina Simultaneously Diagnosed with the Recurrence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Koki Li; Yuki Otsuka; Yasuhiro Nakano; Daisuke Omura; Kou Hasegawa; Mikako Obika; Keigo Ueda; Hitomi Kataoka; Fumio Otsuka
Journal:  Diagnostics (Basel)       Date:  2021-03-06

10.  Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jesús Castro-Marrero; Maria-Cleofé Zaragozá; Irene López-Vílchez; José Luis Galmés; Begoña Cordobilla; Sara Maurel; Joan Carles Domingo; José Alegre-Martín
Journal:  Antioxidants (Basel)       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.